New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups

{
  "signal_id": "2333049f-ddd3-5aa6-885e-e13d77799796",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-12T20:05:00+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/new-tremfya-guselkumab-study-shows-consistent-perianal-fistula-remission-across-key-crohns-disease-patient-subgroups-302906079.html",
    "title": "New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups",
    "excerpt": "SPRING HOUSE, Pa. , Oct. 12, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced new Phase 3 data showing consistent combined fistula remission outcomes with TREMFYA ® (guselkumab) across clinically important subgroups of adults with Crohn's disease with perianal fistula. 1 The prespecified subgroup analyses from the FUZION study are being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and build on previously reported Week 24 results from the overall study population. In the overall study population, 28% of patients receiving TREMFYA 100 mg q8w and 27% receiving TREMFYA 200 mg q4w achieved the composite endpoint of combined fistula remission a at Week 24, compared with 10% receiving placebo, making TREMFYA the only IL-23 inhibitor to demonstrate efficacy in a dedicated, randomized, placebo-controlled trial in patients with Crohn's disease with perianal fistula. 1 New subgroup analyses show consistent outcomes across key patient subgroups Expanding on previously reported results in the overall population, new prespecified subgroup analyses showed greater Week 24 combined fistula remission with TREMFYA versus placebo among: 1 Adverse events were consistent with the known safety profile of TREMFYA in Crohn's disease. 1 \"Perianal fistula remain one of the most debilitating manifestations of moderate to severe Crohn's...",
    "product": "TREMFYA",
    "summary": "Johnson & Johnson announced new Phase 3 data from the FUZION study evaluating TREMFYA (guselkumab) for Crohn's disease patients with perianal fistula.",
    "location": "Spring House, Pennsylvania, USA",
    "planning": true,
    "image_url": "https://mmx.prnewswire.com/media/MS225644/Johnson-and-Johnson-Logo-v1.jpg?id=OA3013168&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "TREMFYA",
      "full_text": "TREMFYA ® (guselkumab)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-12T20:05:00Z",
    "location_data": [
      {
        "city": "Spring House",
        "state": "Pennsylvania",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-12",
    "article_sentence": "Johnson & Johnson (NYSE: JNJ ) today announced new Phase 3 data showing consistent combined fistula remission outcomes with TREMFYA ® (guselkumab) across clinically important subgroups of adults with Crohn's disease with perianal fistula. 1"
  }
}

curl https://signals.autobound.ai/v1/signals/2333049f-ddd3-5aa6-885e-e13d77799796 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'